PHR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who suffered losses between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia made false and misleading statements regarding slowing demand, diminished visibility into key revenue streams, and weakened pharmaceutical marketing commitments in its Network Solutions segment. Investors who incurred losses are encouraged to join the lawsuit, with a deadline of July 13, 2026, to request lead plaintiff appointment.
Flputnam Investment Management Co. Takes $1.66 Million Position in Phreesia, Inc. $PHR
Flputnam Investment Management Co. has acquired a new stake of 160,903 shares in Phreesia, Inc. (NYSE:PHR), valued at approximately $1.66 million, giving it a 0.26% ownership. This move comes as Phreesia shows mixed analyst sentiment, with an average "Hold" rating, but exceeded its Q1 earnings and revenue expectations. The company, which provides patient intake management solutions, has a market capitalization of $713.31 million.
Phreesia (NYSE: PHR) executive has 182 RSU shares withheld
Phreesia, Inc. executive David Linetsky, President, Network Solutions, reported a Form 4 detailing the withholding of 182 shares of common stock at $12.28 per share to cover tax obligations related to Restricted Stock Units. This transaction, dated August 14, 2026, was not an open-market sale. Following the withholding, Linetsky's spouse indirectly holds 11,883 shares, and he directly holds 224,056 shares.
Phreesia, Inc. (PHR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Phreesia, Inc. (NYSE: PHR) securities. The investigation concerns whether Phreesia and its officers and/or directors engaged in corporate wrongdoing. Investors who bought Phreesia securities before March 30, 2026, and still hold them, are encouraged to contact the firm for more information.
PHR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Phreesia, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Phreesia, Inc. (NYSE:PHR) for alleged violations of federal securities laws. The lawsuit claims that Phreesia made false and misleading statements regarding slowing demand, diminished visibility into revenue streams, and weakened pharmaceutical marketing commitments in its Network Solutions segment during the Class Period from May 8, 2025, to March 30, 2026. Shareholders who suffered losses are encouraged to join the lawsuit and have until July 13, 2026, to apply to be lead plaintiff.
Phreesia, Inc. (NYSE:PHR) Given Consensus Rating of "Hold" by Brokerages
Phreesia, Inc. (NYSE:PHR) has received a consensus "Hold" rating from 19 brokerages, with an average 12-month price target of $16.65. Recent analyst updates show mixed views, with some firms lowering price targets while others maintained buy ratings. The company's latest quarterly earnings exceeded expectations, reporting $0.05 EPS against a $0.02 consensus and a 12.9% year-over-year revenue increase.
Phreesia, Inc. $PHR Stake Lessened by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP reduced its stake in Phreesia, Inc. (NYSE:PHR) by 22.9% in the first quarter, selling 143,563 shares and retaining 484,717 shares valued at $4.07 million. Despite this reduction, institutional investors collectively own 92.1% of the company. Phreesia reported strong Q1 earnings with EPS of $0.05, beating estimates, and a 12.9% year-over-year revenue increase to $130.94 million, while analysts currently rate the stock as a "Hold" with an average price target of $16.65.
AQR Capital discloses 5.1% Phreesia (PHR) ownership in new Schedule 13G
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a beneficial ownership of 5.1% in Phreesia, Inc. (PHR) through a new Schedule 13G filing. This amounts to 3,151,453 shares of common stock, with both entities sharing voting and dispositive power. The filing indicates a neutral sentiment and moderate impact for Phreesia.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phreesia, Inc. (PHR) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Phreesia, Inc. (NYSE: PHR) securities who bought prior to March 30, 2026, and still hold their shares. The investigation focuses on whether Phreesia and its officers/directors engaged in corporate wrongdoing. The firm encourages affected shareholders to connect via their website to assist with the investigation, noting there is no cost to investors as they operate on a contingency fee basis.
PHR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Phreesia, Inc. (NYSE:PHR) and its officers. The lawsuit, filed on behalf of investors who purchased Phreesia securities between May 8, 2025, and March 30, 2026, alleges that the company made materially false and misleading statements regarding slowing demand, diminished visibility into revenue streams, and weakened pharmaceutical marketing commitments in its Network Solutions segment. Investors who suffered losses have until July 13, 2026, to request appointment as lead plaintiff.
Phreesia Inc (PHR) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Phreesia Inc (PHR), detailing its current earnings forecast score, average price target from analysts, and a breakdown of analyst ratings. It also includes key financial figures such as expected revenue and EPS for upcoming quarters, alongside a peer comparison. The forecast suggests a positive outlook with most analysts recommending a "Buy" for PHR stock.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Phreesia, Inc. (PHR) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Phreesia, Inc. (NYSE:PHR) concerning potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging shareholders who purchased Phreesia securities before March 30, 2026, and continue to hold them, to learn more and assist with the investigation. The investigation aims to restore investor capital and ensure corporate accountability, with the firm representing investors on a contingency fee basis.
PHR Stockholders Have Opportunity to Lead Phreesia, Inc. Class Ac
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Phreesia, Inc. (NYSE:PHR) and certain officers, alleging federal securities law violations. The lawsuit claims that Phreesia made false and misleading statements regarding slowing demand, diminished revenue visibility, and weakened pharmaceutical marketing commitments between May 8, 2025, and March 30, 2026. Investors who suffered losses have until July 13, 2026, to request to be appointed as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Phreesia, Inc. (PHR) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by Phreesia, Inc. (NYSE:PHR). The firm encourages investors who purchased Phreesia securities prior to March 30, 2026, and still hold them, to join the investigation. The firm operates on a contingency fee basis, meaning no upfront cost to investors.
PHR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce
Bronstein, Gewirtz and Grossman, LLC announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) for alleged federal securities law violations. The lawsuit claims Phreesia made false and misleading statements regarding slowing demand, diminished visibility into revenue streams, and weakened pharmaceutical marketing commitments. Investors who purchased Phreesia securities between May 8, 2025, and March 30, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of July 13, 2026.
PHREESIA, INC. (NYSE: PHR) SHAREHOLDER INVESTIGATION ALERT:
Bernstein Liebhard LLP is investigating potential breaches of fiduciary duty by directors and officers of Phreesia, Inc. (NYSE: PHR). The firm encourages current Phreesia shareholders who purchased shares before May 8, 2025, to contact them to learn about their legal rights. The investigation aims to determine if Company leadership acted in the best interests of shareholders.
PHR Stockholders Have Rights – If You Lost Money Investing in Phreesia, Inc.
Robbins LLP has filed a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia misled investors about the sustainability of its Network Solutions business growth and its fiscal year 2027 revenue outlook. This claim follows a significant drop in Phreesia's stock price after the company lowered its fiscal year 2027 revenue outlook due to weakening pharmaceutical marketing commitments and reduced visibility into future spending.
Phreesia, Inc. (NYSE: PHR) director takes fee as 377 deferred stock units
Phreesia, Inc. director Lainie Goldstein received 377 deferred stock units (DSUs) on July 31, 2026, as an equity-based director fee in lieu of a cash retainer. These DSUs, valued at $10.73 per share, increase her direct holdings to 70,862 shares. The underlying common stock will be issued 90 days after she leaves the board and has a qualifying separation from service under Section 409A.
Phreesia, Inc. (PHR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Phreesia, Inc. (NYSE: PHR). The firm is encouraging shareholders who purchased Phreesia securities before March 30, 2026, and continue to hold them, to contact them for more information and to assist in the investigation. The investigation aims to restore investor capital and ensure corporate accountability.
How Phreesia Inc. (PHR) Affects Rotational Strategy Timing
This article analyzes Phreesia Inc. (PHR) through AI models to determine its effect on rotational strategy timing. It highlights positive near-term sentiment with a potential shift, and no clear price positioning signal, suggesting choppy conditions. The analysis provides specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels, along with multi-timeframe signal analysis for support and resistance.
How Phreesia Inc. (PHR) Affects Rotational Strategy Timing
This article analyzes Phreesia Inc. (PHR) using AI models to determine its impact on rotational strategy timing. It highlights key findings including shifting near-term sentiment, broader weak alignment, and compelling upside potential due to a lack of resistance levels. The analysis also provides three distinct institutional trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) tailored to different risk profiles, along with a multi-timeframe signal analysis indicating varying signal strengths across different horizons.
Phreesia Number of Employees 2026 | Employee Count & Headcount Data
Phreesia, Inc. (PHR) had approximately 1,778 total employees worldwide as of March 2026, marking a 7.1% decline from 1,914 employees in 2023. The company, which is in the Biotech and Healthcare Services industry, is actively hiring with 57 job postings in 2026, despite a significant reduction in hiring velocity. Its workforce is primarily concentrated in North America, and the average salary is $91,777.
PHR|Phreesia Inc|Price:10.740|Chg%:+0.130
Phreesia Inc (PHR) shows relatively healthy fundamentals with high growth potential, and its valuation is considered fairly valued. Despite average stock market performance, the company has turned profitable, and institutional ownership is very high. Analysts have rated it as a Buy, expecting an upward trend in the medium term.
Law firm investigates Phreesia directors for possible breaches of fiduciary duty
Bernstein Liebhard LLP is investigating whether Phreesia, Inc.'s directors and officers breached their fiduciary duties to shareholders. The investigation seeks to determine if the company's leadership acted in the best interests of shareholders and if legal action against them is warranted. Shareholders who purchased stock before May 8, 2025, are encouraged to contact the law firm for a confidential consultation regarding this matter.
PHREESIA, INC. (NYSE: PHR) SHAREHOLDER INVESTIGATION ALERT:
Bernstein Liebhard LLP has announced an investigation into potential breaches of fiduciary duty by directors and officers of Phreesia, Inc. (NYSE: PHR). The firm is encouraging Phreesia shareholders who purchased shares before May 8, 2025, to contact them to discuss their legal rights. The investigation aims to determine if the company's leadership fulfilled its obligations to shareholders and if legal remedies are available.
PHR|Phreesia Inc|Price:10.930|
This article provides an in-depth analysis of Phreesia Inc (PHR) stock, highlighting its market trends, key figures, and analyst ratings. The company, which offers comprehensive software solutions for healthcare organizations, shows healthy fundamentals and high growth potential. Despite average stock performance over the last month, analysts have rated it as a "Buy" with a target price of 13.94, suggesting an expected upward trend in the medium term.
Phreesia Inc (PHR) Income Statement
This article presents the quarterly and annual income statements for Phreesia Inc (PHR), detailing financial performance metrics such as total revenue, cost of revenue, operating expenses, and net income over various fiscal periods. It also includes key financial figures for recent quarters and fiscal years, along with an FAQ section explaining how to interpret the income statement and crucial metrics for stock analysis.
Phreesia Inc (PHR) Balance Sheet
This article provides a detailed balance sheet analysis for Phreesia Inc (PHR), presenting annual and quarterly financial data from FY2020Q1 through FY2027Q1. It breaks down current and non-current assets and liabilities, shareholders' equity, and includes key financial metrics like cash and equivalents, receivables, total assets, total liabilities, and total shareholders' equity. The data allows for evaluation of the company's financial health, liquidity, leverage, and return on equity trends over time.
Phreesia Inc (PHR) Cash Flow
This article provides a detailed overview of Phreesia Inc.'s (PHR) cash flow statements, including operating, investing, and financing activities. It presents quarterly and annual data with year-over-year changes for various cash flow components. The content also defines key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and free cash flow, explaining their significance for investors and providing Phreesia-specific figures for recent periods.
PHR|Phreesia Inc|Price:10.220|Chg%:+0.435
This article provides a detailed company profile for Phreesia Inc (PHR), a provider of healthcare software solutions. It covers the company's business scope, financial data, market performance, and executive information. Phreesia offers SaaS-based tools for patient access, registration, payments, and clinical assessments, aiming to improve operational performance and patient outcomes for healthcare organizations.
Phreesia Inc (PHR) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Phreesia Inc (PHR), outlining its major shareholders, institutional holdings, and related ETFs. It provides a breakdown of shareholder types, institutional activity over several quarters, and a list of top shareholders with their respective holdings and changes.
PHR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce that Phreesia, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) and certain officers for alleged violations of federal securities laws. The lawsuit claims that Phreesia made false and misleading statements regarding slowing demand, diminished revenue visibility, and weakened pharmaceutical marketing commitments, which caused Phreesia's stock to trade at artificially inflated prices. Investors who purchased Phreesia securities between May 8, 2025, and March 30, 2026, are encouraged to join the class action by July 13, 2026.
PHR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce
Bronstein, Gewirtz & Grossman, LLC has announced that a class action lawsuit has been filed against Phreesia, Inc. (NYSE: PHR) and some of its officers. The lawsuit, filed on behalf of investors who purchased Phreesia securities between May 8, 2025, and March 30, 2026, alleges that Phreesia made false and misleading statements regarding slowing demand, diminished revenue stream visibility, and weakened pharmaceutical marketing commitments. Investors who suffered losses have until July 13, 2026, to request to be appointed lead plaintiff in this securities fraud class action.
Preeclampsia and Postpartum Depression Resources Reach Patients Before Visits
Phreesia and March of Dimes have partnered to provide timely, evidence-based educational resources to new parents, caregivers, and healthcare providers to improve maternal and infant health outcomes. This collaboration focuses on raising awareness and providing information on preeclampsia, postpartum depression, and safe sleep practices for infants. The initiative aims to strengthen physician-patient conversations by equipping both parties with relevant information before appointments.
Phreesia Launches AI Chatbot to Connect Patients With Healthcare Providers
Phreesia has launched an AI-powered chatbot designed to streamline patient-provider connections. The new tool aims to improve the healthcare experience by facilitating easier access and communication. This development highlights Phreesia's ongoing efforts to integrate advanced technology into its platform to enhance patient engagement.
Phreesia (PHR) Proxy filing Summary
Phreesia (PHR) has released its proxy filing summary, detailing the upcoming annual meeting on June 24, 2026. Shareholders will vote on electing two Class I directors (Chaim Indig and Jon Kessler), ratifying KPMG LLP as the independent auditor, and conducting a non-binding advisory vote on executive compensation. The board recommends approval of all proposals, emphasizing strong governance, diversity, and shareholder engagement, with board size reducing from nine to seven directors, six of whom will be independent.
PHR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Phreesia, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Phreesia, Inc. (NYSE:PHR) and its officers. The lawsuit alleges that Phreesia made false and misleading statements about its business operations and prospects, specifically regarding slowing demand, diminished revenue stream visibility, and weakened pharmaceutical marketing commitments in its Network Solutions segment. Investors who purchased Phreesia securities between May 8, 2025, and March 30, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of July 13, 2026.
Phreesia (PHR) Proxy filing Summary
This article summarizes Phreesia's (PHR) May 14, 2026 proxy filing, outlining key voting matters for its upcoming annual meeting. Shareholders are asked to vote on the election of two Class I directors, the ratification of KPMG LLP as the independent registered public accounting firm, and an advisory vote on named executive officers' compensation. The board recommends approval of all proposals, emphasizing governance and executive compensation.
Phreesia (PHR) AGM 2026 Summary
This article summarizes Phreesia's (PHR) 2026 Annual General Meeting (AGM) held on June 30, 2026. Key items included the election of two Class I directors, ratification of KPMG as the independent auditor, and a non-binding advisory vote on executive compensation for FY 2026. The meeting also introduced present directors, officers, and independent auditors.
Phreesia Principal Accounting Officer Yvonne Hui disposes of 1,247 common shares worth $13,623.24
Phreesia's Principal Accounting Officer, Yvonne Hui, reduced her stake by disposing of 1,247 common shares worth $13,623.24. This transaction, part of larger sales on July 15-16, decreased her total holding to 21,724 common shares. The news brief is generated by AI based on information from Phreesia Inc. via EDGAR.
Form 4 Phreesia Inc For: 17 July By Investing.com
This article reports on the Form 4 filing for Phreesia Inc, specifically detailing transactions that occurred on July 17th. It provides basic information about the filing and links to further details, indicating that it is a routine financial disclosure document. The content primarily focuses on the stock market aspect, mentioning Phreesia's stock symbol PHR.
Phreesia (NYSE: PHR) executive logs RSU tax share withholding
Phreesia, Inc. executive David Linetsky, President, Network Solutions, reported an equity activity where 69 shares of common stock were withheld by the company to satisfy tax withholding obligations related to restricted stock units. This transaction, occurring on July 15, 2026, at $10.76 per share, was not a sale. After the transaction, Linetsky holds 224,056 direct shares and 12,065 indirect shares through his spouse.
Phreesia (NYSE: PHR) officer sells 1,247 shares in 10b5-1 plan
Yvonne Hui, Phreesia's Principal Accounting Officer, sold 1,247 shares of common stock at $10.92 per share on July 16, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. This transaction followed the withholding of 937 shares on July 15, 2026, to cover tax obligations related to restricted stock units. After these transactions, Hui directly holds 21,724 shares of Phreesia common stock.
PHREESIA, INC. (PHR) INVESTIGATION ALERT: Bernstein Liebhard Announces Investigation of Phreesia, Inc.
Bernstein Liebhard LLP has announced an investigation into Phreesia, Inc. (NYSE: PHR) to determine if its directors and officers breached fiduciary duties. Shareholders who purchased shares before May 8, 2025, are encouraged to contact the firm to discuss their legal rights and options. Bernstein Liebhard LLP is an investor rights law firm that has recovered over $3.5 billion for clients since 1993.
Insider Sell Alert: Lisa Egbuonu-davis Sells Shares of Phreesia Inc (PHR)
Lisa Egbuonu-davis, a Director at Phreesia Inc (PHR), sold 536 shares of the company on July 14, 2026, reducing her holdings to 37,780 shares. This transaction is part of a trend with 1 insider buy and 57 insider sells at Phreesia over the past year. The stock is currently trading at $10.70 with a GF Value of $27.04, indicating it might be a "Possible Value Trap."
Phreesia (NYSE: PHR) director sells 536 shares in pre-set 10b5-1 trade
Phreesia, Inc. director Lisa Egbuonu-Davis reported an open-market sale of 536 shares of common stock on July 14, 2026, at a price of $10.70 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted in December 2025. Following the sale, Lisa Egbuonu-Davis directly holds 37,780 shares of the company.
Phreesia director Lisa Egbuonu-Davis sells $5,735 in stock
Phreesia director Lisa Egbuonu-Davis sold 536 shares of Phreesia, Inc. stock for $5,735 on July 14, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, she directly holds 37,780 shares. The company recently reported strong Q1 fiscal 2027 earnings, surpassing expectations, though analyst ratings show varied outlooks.
Phreesia, Inc. SEC Filing
This SEC filing (Form 144) for Phreesia, Inc. (PHR) details Yvonne Hui's intent to sell 1,247 shares of common stock, valued at $13,617.24, acquired through restricted stock vesting. The filing also reports several previous sales of PHR common stock by Yvonne Hui within the last three months. The transaction is set to occur via Fidelity Brokerage Services LLC on the NYSE.
PHREESIA, INC. (PHR) INVESTIGATION ALERT: Bernstein Liebhard Announces Investigation of Phreesia, Inc.
Bernstein Liebhard LLP, a prominent investor rights law firm, has initiated an investigation into Phreesia, Inc. (NYSE: PHR) regarding potential breaches of fiduciary duties by certain directors and officers. The firm is reaching out to current Phreesia shareholders, particularly those who acquired shares before May 8, 2025, to discuss their legal rights and options. Bernstein Liebhard LLP has a strong track record, having recovered over $3.5 billion for clients since 1993.
PHR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Phreesia, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit filed against Phreesia, Inc. (NYSE:PHR) and its officers. The lawsuit alleges that Phreesia made false and misleading statements about its business, operations, and prospects between May 8, 2025, and March 30, 2026, stemming from slowing demand and weakened pharmaceutical marketing commitments. Investors who purchased Phreesia securities during this period have until July 13, 2026, to apply to be lead plaintiff.
